Biochimpharm

Biochemistry is a phage-producing company which is aimed at maximizing the long-term experience of phagicides in order to simplify the fight against bacterial infections.

In 2017, SavvY created a financial model for a new production unit of Biochimpharm and evaluated the existing project: its investment volume, assumptions, profitability, cost, and revenue structure. Using a 5-year financial model, the company’s project was assessed reliably for investors.

Client
Biochimpharm
Date
17/02/2017
Services
Financial Modeling